CEFTEM 1.5 GM

Name: CEFTEM 1.5 GM
Brand: Curezone Pharma Private Limited
Price: 25.0 INR
Availability: InStock

Price 25.0 INR/ Piece

Get a Price/Quote

MOQ : 100 Pieces

CEFTEM 1.5 GM Specification

Origin of Medicine
Indian

Indication
Treatment of severe infections

Packaging Type
Glass Vial

Salt Composition
Ceftriaxone 1 gm + Tazobactam 0.5 gm

Life Span
24 Months

Pacakaging (Quantity Per Box)
Each box contains 1 vial with sterile water for injection

Dosage Form
Injection

Drug Type
Allopathic

Ingredients
Ceftriaxone and Tazobactam

Physical Form
Powder for Injection

Function
Antibiotic

Recommended For
Bacterial infections

Dosage
As directed by the physician

Dosage Guidelines
Take as per prescription

Suitable For
Adults

Quantity
1.5 gm

Storage Instructions
Store in a cool, dry place

Reconstitution
To be reconstituted with sterile water before use

Additive
With Sterile Water for Injection

Route of Administration
Intravenous or Intramuscular

Therapeutic Class
Third Generation Cephalosporin with Beta-lactamase inhibitor

Manufactured By
Aglowmed

Color
White to off-white powder

Prescription Status
Prescription only

Product Form
Lyophilized Powder

Application Area
Hospital/Clinical

Shelf Life (after reconstitution)
Use immediately after reconstitution

CEFTEM 1.5 GM Trade Information

Minimum Order Quantity
100 Pieces

Delivery Time
7 Days

About CEFTEM 1.5 GM

Explore the trending and highlighted CEFTEM 1.5 GM, an incomparable antibiotic featuring Ceftriaxone and Tazobactam, crafted by Aglowmed for enlightened medical professionals. Suitable for intravenous or intramuscular administration, this breathtaking third-generation cephalosporin with a beta-lactamase inhibitor is ideal for treating severe bacterial infections in adults. Supplied as a white to off-white lyophilized powder, each glass vial pairs with sterile water for swift reconstitution-recommended for use in hospital or clinical environments. Store cool and dry; use strictly under prescription, ensuring optimal safety and efficacy.

Diverse Clinical Applications & Unmatched Advantages

CEFTEM 1.5 GM stands out in hospital and clinical settings for its potent fight against severe bacterial infections. Its primary competitive advantage lies in the synergistic use of Ceftriaxone and Tazobactam, enabling a broader spectrum of action. This product is suited for general antibacterial therapy and specific critical cases where an advanced approach is essential. Engineered for immediate use post-reconstitution, it facilitates efficient patient care in high-stakes environments.

Flexible Payment, Verified Quality & Export Market Support

Payment options for CEFTEM 1.5 GM are tailored to your institutional needs, ensuring a seamless transaction process. Certifications validate the quality and safety of every vial, meeting stringent regulatory standards. Sample vials can be handed over upon request, enabling evaluation before wider adoption. Timely delivery is assured for both domestic and export market partners, confirming Aglowmed's commitment to global healthcare excellence.

FAQ's of CEFTEM 1.5 GM:

Q: How is CEFTEM 1.5 GM administered in a clinical setting?

A: CEFTEM 1.5 GM is administered via intravenous or intramuscular injection after reconstitution with the provided sterile water, ensuring immediate effectiveness in combating infections.

Q: What bacteria-related conditions is CEFTEM 1.5 GM recommended for?

A: This injection is prescribed for severe bacterial infections, covering a wide array of pathogens due to the combined power of Ceftriaxone and Tazobactam.

Q: When should CEFTEM 1.5 GM be used after reconstitution?

A: It should be used immediately after reconstitution to maintain its therapeutic potency and minimize the risk of contamination.

Q: Where should CEFTEM 1.5 GM be stored before use?

A: Keep the product in a cool, dry place and store the reconstituted injection as per the guidelines; use immediately after preparation.

Q: What is the advantage of combining Ceftriaxone with Tazobactam in CEFTEM 1.5 GM?

A: The combination enhances antibacterial efficacy, overcoming beta-lactamase-producing resistant bacteria and offering broadened therapeutic coverage.